CDMO Andelyn Biosciences says that it has manufactured a viral vector with its AAV Curator® Platform for the Nationwide Children’s Hospital’s Cellular Therapy and Cancer Immunology Program. The Adeno-Associated Virus (AAV) will be utilized in a novel cell therapy for Universal-Donor CD38KO CD33CAR-NK cells, to be studied in a forthcoming clinical trial. The Phase I trial will study the safety of the novel therapy in patients with advanced, high-risk acute myeloid leukemia (AML).
“We are excited to be playing a key role in this promising Universal Donor CD38KO CD33CAR-NK cell therapy technology by NCH,” said Matt Niloff, the company’s chief commercial officer. “We look forward to the clinical trial ushering in a new era for patients with AML and other blood cancers.”
The post Andelyn’s Platform Used to Manufacture Clinical Grade Viral Vector appeared first on GEN - Genetic Engineering and Biotechnology News.
“We are excited to be playing a key role in this promising Universal Donor CD38KO CD33CAR-NK cell therapy technology by NCH,” said Matt Niloff, the company’s chief commercial officer. “We look forward to the clinical trial ushering in a new era for patients with AML and other blood cancers.”
The post Andelyn’s Platform Used to Manufacture Clinical Grade Viral Vector appeared first on GEN - Genetic Engineering and Biotechnology News.